Literature DB >> 9851542

Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat.

E Lazartigues1, J L Freslon, T Tellioglu, C Brefel-Courbon, M Pelat, M A Tran, J L Montastruc, O Rascol.   

Abstract

The cardiovascular effects of three different acetylcholinesterase inhibitors: physostigmine, tacrine and rivastigmine injected by intravenous (i.v.) route were compared in freely moving Wistar rats. The three drugs significantly increased both systolic and diastolic blood pressure and decreased heart rate. Compared to physostigmine, a 20-fold higher dose of tacrine and a 40-fold higher dose of rivastigmine was necessary to induce a comparable pressor effect. Tacrine was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. cholinesterase inhibitors. Atropine totally abolished while methylatropine did not affect tacrine pressor effects. Conversely, both drugs abolished tacrine-induced bradycardia. The alpha1-adrenoceptor antagonist prazosin or the vasopressin V1 receptor antagonist, [beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin partially but significantly reduced tacrine pressor effect and mostly abolished it when administered concomitantly. The tacrine pressor response was inhibited in a dose-dependent manner by the i.c.v. administration of the non-selective muscarinic receptor antagonist atropine (ID50 = 1.45 microg), the muscarinic M1 receptor antagonist pirenzepine (ID50 = 4.33 microg), the muscarinic M2 receptor antagonist methoctramine (ID50 = 1.39 microg) and the muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol (ID50 = 31.19 microg). Central injection of such muscarinic receptor antagonists did not affect tacrine-induced bradycardia. Our results show that acetylcholinesterase inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central muscarinic M2 receptors inducing a secondary increase in sympathetic outflow and vasopressin release. Conversely, acetylcholinesterase inhibitor-induced bradycardia appears to be mediated by peripheral muscarinic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851542     DOI: 10.1016/s0014-2999(98)00717-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Pyridostigmine in the treatment of orthostatic hypotension.

Authors:  Jean-Michel Senard
Journal:  Clin Auton Res       Date:  2005-12       Impact factor: 4.435

2.  Spontaneously hypertensive rats cholinergic hyper-responsiveness: central and peripheral pharmacological mechanisms.

Authors:  E Lazartigues; C Brefel-Courbon; M A Tran; J L Montastruc; O Rascol
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 3.  Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

Authors:  B P Imbimbo
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  The effect of donepezil treatment on cardiovascular mortality.

Authors:  K Sato; R Urbano; C Yu; F Yamasaki; T Sato; J Jordan; D Robertson; A Diedrich
Journal:  Clin Pharmacol Ther       Date:  2010-07-21       Impact factor: 6.875

5.  No significant effects of single intravenous, single oral and subchronic oral administration of acetylcholinesterase inhibitors on striatal [123I]FP-CIT binding in rats.

Authors:  R J J Knol; K de Bruin; B L F van Eck-Smit; J Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-23       Impact factor: 9.236

6.  Autonomic and cholinergic mechanisms mediating cardiovascular and temperature effects of donepezil in conscious mice.

Authors:  Aaron J Polichnowski; Geoffrey A Williamson; Tesha E Blair; Donald B Hoover
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-04-14       Impact factor: 3.210

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.